Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03944057 · FLOW

Participant flow

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma · Source last updated 2023-06-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Open-label ATG-010 80mg plus Dexamethasone 20 mg ATG-010: ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle). Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)
    id
    FG000
    title
    ATG-010 + Dexamethasone
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        82
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        82
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Open-label ATG-010 80mg plus Dexamethasone 20 mg ATG-010: ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle). Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)
    id
    FG000
    title
    ATG-010 + Dexamethasone
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        82
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        82
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice